Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of $10.95.
A pharmacist and a customer discussing a novel therapeutic oral health product in a pharmacy.
Haleon plc (NYSE:HLN) reported unaudited results for H1 2025 on June 30, reporting notable growth in EMEA & LatAm and Asia-Pacific, while showing continued outperformance in Oral Health.
Management reported organic revenue growth across EMEA & LatAm (+5.2%) and Asia-Pacific (+5.0%), partially offsetting a 0.4% decline in North America. The trends reflected a weak US consumer and retail environment.
The company also reported that 58% of businesses gained or maintained market share, suggesting the resilience of its brand portfolio. Free cash flow for the first half of the year reached £734 million, up £184 million year-on-year, primarily due to progress on working capital initiatives.
Haleon plc (NYSE:HLN) provides personal healthcare products, with a focus on consumer healthcare. The company’s operations are divided into the following geographical segments: North America, EMEA and LatAm, and Asia Pacific.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
